DISCOVERY LABS' SURFAXIN GETS SECOND APPROVABLE LETTER FROM FDA

Discovery Laboratories has received a second approvable letter from the FDA for the company's lead product candidate, Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants.

Surfaxin is a precision-engineered, peptide-containing, synthetic surfactant that is designed to closely mimic the function of natural human lung surfactant and represents a potential alternative to animal-derived surfactants.